These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11827928)

  • 21. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model.
    Semsarian C; Ahmad I; Giewat M; Georgakopoulos D; Schmitt JP; McConnell BK; Reiken S; Mende U; Marks AR; Kass DA; Seidman CE; Seidman JG
    J Clin Invest; 2002 Apr; 109(8):1013-20. PubMed ID: 11956238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of Gαi2 leads to dilative cardiomyopathy and increased mortality in β1-adrenoceptor overexpressing mice.
    Keller K; Maass M; Dizayee S; Leiss V; Annala S; Köth J; Seemann WK; Müller-Ehmsen J; Mohr K; Nürnberg B; Engelhardt S; Herzig S; Birnbaumer L; Matthes J
    Cardiovasc Res; 2015 Dec; 108(3):348-56. PubMed ID: 26464333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy.
    Patel R; Nagueh SF; Tsybouleva N; Abdellatif M; Lutucuta S; Kopelen HA; Quinones MA; Zoghbi WA; Entman ML; Roberts R; Marian AJ
    Circulation; 2001 Jul; 104(3):317-24. PubMed ID: 11457751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypertrophy, fibrosis, and sudden cardiac death in response to pathological stimuli in mice with mutations in cardiac troponin T.
    Maass AH; Ikeda K; Oberdorf-Maass S; Maier SK; Leinwand LA
    Circulation; 2004 Oct; 110(15):2102-9. PubMed ID: 15466629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ca2+-independent alterations in diastolic sarcomere length and relaxation kinetics in a mouse model of lipotoxic diabetic cardiomyopathy.
    Flagg TP; Cazorla O; Remedi MS; Haim TE; Tones MA; Bahinski A; Numann RE; Kovacs A; Schaffer JE; Nichols CG; Nerbonne JM
    Circ Res; 2009 Jan; 104(1):95-103. PubMed ID: 19023131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fropofol prevents disease progression in mice with hypertrophic cardiomyopathy.
    Huang Y; Lu H; Ren X; Li F; Bu W; Liu W; Dailey WP; Saeki H; Gabrielson K; Abraham R; Eckenhoff R; Gao WD
    Cardiovasc Res; 2020 May; 116(6):1175-1185. PubMed ID: 31424496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Murine Hypertrophic Cardiomyopathy Model: The DBA/2J Strain.
    Zhao W; Zhao T; Chen Y; Zhao F; Gu Q; Williams RW; Bhattacharya SK; Lu L; Sun Y
    PLoS One; 2015; 10(8):e0133132. PubMed ID: 26241864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac and skeletal muscle expression of mutant β-myosin heavy chains, degree of functional impairment and phenotypic heterogeneity in hypertrophic cardiomyopathy.
    Di Domenico M; Casadonte R; Ricci P; Santini M; Frati G; Rizzo A; Carratelli CR; Lamberti M; Parrotta E; Quaresima B; Faniello CM; Costanzo F; Cuda G
    J Cell Physiol; 2012 Oct; 227(10):3471-6. PubMed ID: 22213221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (β-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy.
    Weissler-Snir A; Hindieh W; Gruner C; Fourey D; Appelbaum E; Rowin E; Care M; Lesser JR; Haas TS; Udelson JE; Manning WJ; Olivotto I; Tomberli B; Maron BJ; Maron MS; Crean AM; Rakowski H; Chan RH
    Circ Cardiovasc Imaging; 2017 Feb; 10(2):. PubMed ID: 28193612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myosin regulatory light chain mutation found in hypertrophic cardiomyopathy patients increases isometric force production in transgenic mice.
    Kazmierczak K; Muthu P; Huang W; Jones M; Wang Y; Szczesna-Cordary D
    Biochem J; 2012 Feb; 442(1):95-103. PubMed ID: 22091967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertrophic cardiomyopathy R403Q mutation in rabbit β-myosin reduces contractile function at the molecular and myofibrillar levels.
    Lowey S; Bretton V; Joel PB; Trybus KM; Gulick J; Robbins J; Kalganov A; Cornachione AS; Rassier DE
    Proc Natl Acad Sci U S A; 2018 Oct; 115(44):11238-11243. PubMed ID: 30322937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation.
    Georgakopoulos D; Christe ME; Giewat M; Seidman CM; Seidman JG; Kass DA
    Nat Med; 1999 Mar; 5(3):327-30. PubMed ID: 10086390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic suppression of Gαs protein provides rate control in atrial fibrillation.
    Lugenbiel P; Thomas D; Kelemen K; Trappe K; Bikou O; Schweizer PA; Voss F; Becker R; Katus HA; Bauer A
    Basic Res Cardiol; 2012 May; 107(3):265. PubMed ID: 22457123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of myocardial Gsalpha prevents full expression of catecholamine desensitization despite increased beta-adrenergic receptor kinase.
    Vatner DE; Asai K; Iwase M; Ishikawa Y; Wagner TE; Shannon RP; Homcy CJ; Vatner SF
    J Clin Invest; 1998 May; 101(9):1916-22. PubMed ID: 9576756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy.
    Nebigil CG; Jaffré F; Messaddeq N; Hickel P; Monassier L; Launay JM; Maroteaux L
    Circulation; 2003 Jul; 107(25):3223-9. PubMed ID: 12810613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice.
    Turki J; Lorenz JN; Green SA; Donnelly ET; Jacinto M; Liggett SB
    Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10483-8. PubMed ID: 8816827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy.
    Witjas-Paalberends ER; Piroddi N; Stam K; van Dijk SJ; Oliviera VS; Ferrara C; Scellini B; Hazebroek M; ten Cate FJ; van Slegtenhorst M; dos Remedios C; Niessen HW; Tesi C; Stienen GJ; Heymans S; Michels M; Poggesi C; van der Velden J
    Cardiovasc Res; 2013 Aug; 99(3):432-41. PubMed ID: 23674513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.
    Green EM; Wakimoto H; Anderson RL; Evanchik MJ; Gorham JM; Harrison BC; Henze M; Kawas R; Oslob JD; Rodriguez HM; Song Y; Wan W; Leinwand LA; Spudich JA; McDowell RS; Seidman JG; Seidman CE
    Science; 2016 Feb; 351(6273):617-21. PubMed ID: 26912705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein.
    Gaffin RD; Peña JR; Alves MS; Dias FA; Chowdhury SA; Heinrich LS; Goldspink PH; Kranias EG; Wieczorek DF; Wolska BM
    J Mol Cell Cardiol; 2011 Nov; 51(5):812-20. PubMed ID: 21840315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy.
    Nagueh SF; Kopelen HA; Lim DS; Zoghbi WA; Quiñones MA; Roberts R; Marian AJ
    Circulation; 2000 Sep; 102(12):1346-50. PubMed ID: 10993850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.